Information Provided By: 
Fly News Breaks for August 11, 2017
TXMD
Aug 11, 2017 | 07:23 EDT
After the FDA said it would review additional data from TherapeuticsMD on vaginal estrogen use and set a November 3 meeting date with the company, Stifel analyst Annabel Samimy thinks the FDA's moves indicate "the data are meaningful enough to satisfy the safety question in the CRL." She thinks that the company's program may be no more than six months delayed from the original plan, and she keeps a $20 price target and a Buy rating on the shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
